Edition:
India

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.04USD
16 Feb 2018
Change (% chg)

$-2.15 (-67.40%)
Prev Close
$3.19
Open
$1.04
Day's High
$1.31
Day's Low
$0.93
Volume
2,581,273
Avg. Vol
105,695
52-wk High
$3.48
52-wk Low
$0.87

Chart for

About

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $25.95
Shares Outstanding(Mil.): 12.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

16 Feb 2018

BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros

* APRICUS BIOSCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR VITAROS

16 Feb 2018

U.S. FDA declines to approve Apricus' erectile dysfunction cream

Feb 16 Apricus Biosciences Inc said on Friday the U.S. Food and Drug Administration declined to approve Vitaros, a cream-based treatment for erectile dysfunction, in its present form.

16 Feb 2018

BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million

* Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing Source text : (http://bit.ly/2gZ2TjB) Further company coverage:

03 Nov 2017

BRIEF-Apricus Biosciences files for resale of up to 3.3 mln of common stock by selling stockholders

* Apricus Biosciences Inc files for resale of up to 3.3 million of common stock by selling stockholders - SEC Filing Source text :(http://bit.ly/2y3YztZ) Further company coverage:

26 Sep 2017

BRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co

* Armistice Capital LLC reports 9.6 percent passive stake in Apricus Biosciences Inc, as of September 10, 2017 - SEC filing ‍​ Source text: [http://bit.ly/2xgpiTr] Further company coverage:

21 Sep 2017

BRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-market

* Apricus Biosciences announces $3.7 million private placement priced at-the-market

11 Sep 2017

BRIEF-Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

* Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

31 Aug 2017

BRIEF-Apricus Biosciences files NDA resubmission for Vitaros

* Apricus Biosciences Inc - Apricus anticipates a six-month review by FDA with a projected PDUFA goal date in Q1 of 2018 Source text for Eikon: Further company coverage:

29 Aug 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
GlaxoSmithKline plc (GSK.L) 1,318.60 +18.20
Eli Lilly and Co (LLY.N) $78.97 +0.95
Abbott Laboratories (ABT.N) $60.17 +0.67

Earnings vs. Estimates